Saad Ahmad, MD
Critical Care Medicine · Bay City, MINPI 1750562153
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 25.6% of the total. Reporting peaked in 2019 at $682 and has fallen 62.0% since, to $259 in 2025.
Across 118 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$552
- AstraZeneca$345
- Boehringer Ingelheim$222
- Mylan Specialty L.p.$119
- Grifols USA, LLC$105
- Pfizer$100
- plus $711 from 22 others
What the payments were for
- Food & beverage$2,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 33 | $552 |
| AstraZeneca | 24 | $345 |
| Boehringer Ingelheim | 12 | $222 |
| Mylan Specialty L.p. | 6 | $119 |
| Grifols USA, LLC | 6 | $105 |
| Pfizer | 1 | $100 |
| Pulmonx Corporation | 3 | $72 |
| Insmed, Inc. | 3 | $59 |
| Actelion Pharmaceuticals US, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Viatris Specialty LLC | 2 | $42 |
| Verona Pharma, Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 3 | $42 |
| Shockwave Medical, Inc | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Neurotech Pharmaceuticals, Inc. | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Electromed, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Philips North America LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Inogen, Inc. | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,155 in reported general payments places this provider in the 85th percentile of 177 critical care medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 261 | $261,542 |
| Spiriva RespimatTiotropium Bromide | 118 | $83,224 |
| Breo ElliptaFluticasone/Vilanterol | 121 | $68,304 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $18,197 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $12,422 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $9,604 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $7,556 |
| Tiotropium Bromide | 12 | $6,436 |
| Roflumilast | 40 | $4,571 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $4,503 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 132 | $4,402 |
| Fluticasone Propionate HfaFluticasone Propionate | 12 | $3,244 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $2,853 |
| Ventolin HfaAlbuterol Sulfate | 28 | $1,605 |
| Montelukast Sodium | 22 | $343 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $552 | $342,267409 claims |
| Boehringer IngelheimSpiriva Respimat | $222 | $83,224118 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $345 | $25,75346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 critical care medicine providers in Michigan.
Other critical care medicine in Bay City
- Angel Peralta-AvilaDetroit$147K
- Moumen AsbahiTroy$81K
- Mujahed AbbasLansing$28K
- Abdulrazak AlchakakiSouthfield$19K
- Narayana GandhamSaint Joseph$18K
- Sara MirzaAnn Arbor$12K
- Asker AsmiRiverview$11K
- Andrew EasowDearborn$10K
- Jeffery WiltGrand Rapids$10K
- Furqan SiddiqiSaint Joseph$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.